Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 570 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03858205Recruiting
Low-dose radiation to relieve pain from bone tumors
This trial studies whether low-dose radiation can reduce pain from a specific bone lesion caused by multiple myeloma. It may help people whose main problem is painful bone metastasis, with targeted treatment to the painful spot.
Duarte, CaliforniaAges 18 years+ - NCT03308474Recruiting
Myeloma patient registry study for treatment experiences
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
Multiple SitesAges 18 years+ - NCT02726750Recruiting
Study of early plasma cell blood conditions before myeloma
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
Houston, TexasAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Boston, MassachusettsAges 18 years+ - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Gilbert, ArizonaAges 18 years+ - NCT01408225Recruiting
Myeloma and amyloidosis patient data and sample registry
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
Columbus, OhioAges 18 years+ - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Sacramento, CaliforniaAges 2 months+ - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Miami, FloridaAges 18 years+ - NCT06430736RecruitingPhase 2
Tocilizumab before or during CAR-T therapy
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Bern, Canton of BernAges 18 years+ - NCT04662294RecruitingEarly Phase 1
CD70-targeted CAR T therapy for CD70-positive blood cancers
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hangzhou, ZhejiangAges Any age - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT05594797RecruitingPhase 2
BCMA CAR-T for multiple myeloma that came back or stopped working
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06045091RecruitingEarly Phase 1
BCMA-targeted CAR-NK cells for multiple myeloma or plasma cell leukemia
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03131531Recruiting
Lymphoid cancer registry for lymphoma and myeloma patients
This study is a cancer registry that collects information from people with lymphoma, Hodgkin disease, or myeloma. It helps researchers understand these cancers better by using real-world patient data.
BergamoAges 18 years+ - NCT06182696RecruitingPhase 1/Phase 2
CAR-T cells targeting GPRC5D for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets a protein called GPRC5D on myeloma cells. It is for people with multiple myeloma that has come back or not responded to several prior treatments, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies.
Hangzhou, ZhejiangAges 18–75 - NCT07850284Recruiting
Text message symptom check-ins for blood cancer patients
This study uses text messages to check how you're feeling during cancer treatment. It may help your care team respond sooner to symptoms and improve your quality of life.
Rochester, MinnesotaAges 18 years+ - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75 - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT06271252RecruitingPhase 1
Study of OriCAR-017 for relapsed or refractory multiple myeloma
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Atlanta, GeorgiaAges 18–75 - NCT06541860Recruiting
Study of daratumumab and lenalidomide for resistant multiple myeloma
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
Pavia, PVAges 18 years+ - NCT07777406Recruiting
Real-world study of donor stem cell transplant for relapsed/refractory myeloma
This study looks at real-world outcomes in patients who have had a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to gather info on how well this approach works in everyday practice.
Chieti, CHAges 18 years+ - NCT06187441RecruitingPhase 3
Testing a treatment break in multiple myeloma
This trial is for people with multiple myeloma who have already completed 12 cycles of a standard treatment (daratumumab, lenalidomide, and dexamethasone) and are doing well. It tests whether taking a break from treatment is safe and effective, instead of continuing without a break.
's-HertogenboschAges 18 years+ - NCT07763054Recruiting
Low-dose antifungal prevention for patients with low white blood cell counts
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Hainan, HainanAges 18–75
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 570 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.